AMPH Q4 2020 Earnings — Amphastar Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMPHAmphastar Pharmaceuticals, Inc.

$894M

Q4 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$96M+15.0% YoY

Gross Profit

$37M38.4% margin

Operating Income

$3M3.0% margin

Net Income

-$6M-6.5% margin

EPS (Diluted)

$-0.13

QoQ Revenue Growth

+15.0%

Cash Flow

Operating Cash Flow

$17M

Free Cash Flow

$8M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$631M

Total Liabilities

$183M

Stockholders' Equity

$402M

Cash & Equivalents

$93M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$96M	$83M	+15.0%
Gross Profit	$37M	$33M	+10.3%
Operating Income	$3M	-$244,000	+1279.9%
Net Income	-$6M	-$1M	-511.4%

Revenue Segments

Active Pharmaceutical Ingredient Segment

$8M100%

Geographic Segments

U

$91M99%

C

$679,0001%